Tag
This study evaluates the societal cost-effectiveness of oral antihyperglycemic agents compared to insulin for gestational diabetes treatment, showing oral agents offer comparable benefits at potentially lower costs with small quality-adjust
This study evaluates when thoracentesis or thoracoscopy is more cost-effective in diagnosing malignant pleural effusion in patients with prior or active malignancy, highlighting thresholds of pleural fluid cytology sensitivity guiding optim
This review synthesizes evidence on the cost-effectiveness of standalone salpingectomy for ovarian cancer prevention, highlighting its benefits primarily in women at moderately elevated risk, especially between ages 45-50, supporting tailor
This study compares robotic and laparoscopic cholecystectomy, highlighting robotic surgery’s advantages in safety for high-risk and obese patients despite higher costs, and introduces a predictive risk calculator to aid surgical decis
This randomized trial analysis compares the costs and quality-adjusted life years of robotic versus open pancreatoduodenectomy, revealing no significant cost differences but a lower probability that robotic surgery is cost-effective at six
This review synthesizes current evidence on menopausal hormone therapy’s cost-effectiveness, highlighting findings from a 2026 Markov model analysis and contextualizing with pivotal studies on health outcomes and economic implications
This review synthesizes current evidence on adalimumab, secukinumab, and bimekizumab for moderate-to-severe hidradenitis suppurativa, emphasizing clinical efficacy, safety, mechanistic insights, and cost-effectiveness across diverse health
The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.
Oral nicotinamide reduces keratinocyte carcinoma incidence in high-risk individuals, providing significant cost savings and quality-adjusted life-year gains, supporting its role as a cost-effective preventive strategy.
Medicare Advantage beneficiaries with cancer receive guideline-concordant treatment similarly to Traditional Medicare enrollees but at lower costs and comparable timeliness, highlighting implications for healthcare policy and cost-effective
A retrospective cohort study of ACCESS Open Minds in Canada demonstrates significant cost savings and improved service utilization in youth mental health care through enhanced, community-based services.
This review synthesizes evidence on the cost-effectiveness of the FMF first-trimester screening strategy for preterm preeclampsia in the UK compared to NICE recommendations, highlighting clinical efficacy, economic benefits, and implication
Pembrolizumab plus chemoradiotherapy improved survival and quality-adjusted survival for FIGO 2014 stage III-IVA cervical cancer and was projected to be cost-effective in the U.S. at a $150,000/QALY threshold.
A comprehensive simulation study evaluates the cost-effectiveness of semaglutide for secondary cardiovascular prevention in US adults without diabetes, finding significant health benefits but highlighting the need for price reductions to en
A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic
The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its hi
The 10-year TOPKAT randomized trial found no clinically important difference in Oxford Knee Score between partial (PKR) and total knee replacement (TKR) for medial compartment osteoarthritis, similar revision/reoperation rates, and cost-eff
A modeling study found that sequential population screening for familial hypercholesterolemia (FH) at ages 10 or 18 is clinically effective but not cost‑effective versus usual care, unless follow-up monitoring and lifestyle interventions fo
AEDs improve survival in in-home cardiac arrests with shockable rhythms but are not cost-effective for widespread private home use at current prices and incidence rates, per a large US cohort study using CARES data.
This economic evaluation from the CYCLE randomized trial found no significant cost or quality-adjusted life-year benefit by adding early in-bed cycling to usual physiotherapy for ICU patients on mechanical ventilation, underscoring a need f
